Get the App
Join our growing community to challenge mainstream media bias and fix the news
Gilead to buy cancer drugmaker Immunomedics in $21 billion deal

Gilead to buy cancer drugmaker Immunomedics in $21 billion deal

Gilead Sciences Inc. is nearing a deal to buy biotech Immunomedics Inc. for more than $20bn. The deal will provide Gilead access to the drug Trodelvy, an FDA-approved treatment for metastatic triple-negative breast cancer. The offer will be funded through about $15 billion in cash on hand and $6 billion in newly issued debt. The transaction is anticipated to close in the fourth quarter of 2020.

KCooper
KCooper
David Webb
David Webb 2 weeks

Just shows how much money there is in not curing cancer.

Top in Business